Parameter | Ivacaftor | Lumacaftor/Ivacaftor | Tezacaftor/Ivacaftor |
---|---|---|---|
Active Ingredients | Ivacaftor 150mg | Lumacaftor 200mg/Ivacaftor 125mg | Tezacaftor 100mg/Ivacaftor 150mg |
Indications | G551D mutation & other gating mutations | F508del homozygous | F508del heterozygous |
Dosing Frequency | Q12H | Q12H | Q12H |
FDA Approval Year | 2012 | 2015 | 2018 |
Ivacaftor demonstrates exceptional efficacy in:
Optimal Administration Protocol:
Case Study 1: 24yo male G551D mutation
Case Study 2: Pediatric patient R117H mutation
University Hospital Implementation:
Regional Healthcare Network:
Contact our therapeutic specialists for:
Email: info@vivalr.com
Phone: (86) 15866781826
Ivacaftor's pharmacokinetic profile shows:
Mutation Type | FEV1 Improvement | Sweat Chloride Reduction |
---|---|---|
G551D | 16.7% | 48.1mmol/L |
R117H | 9.3% | 34.6mmol/L |
Phase III trials demonstrated:
This is William, CEO of fousi chemical Chemical Co., Ltd.
Welcome to visit our factory . As the top chemical manufacturer, we have been striving for product quality, innovation , R&D, and customer service for the past 7 years. In the next 10 years or even longer, we are committed to becoming the most reliable chemical supplier in the world , creating a well-known international brand trusted by customers, with the spirit of “one meter wide, ten thousand meters deep”, we continue to focus on product research and development, continue to focus on customer service, continue to improve the supply chain service system, to create a professional chemical supply service team, to achieve win-win long-term cooperation. Please feel free to contact us if you have any questions.